Bayer CropScience Limited Logo

Bayer CropScience Limited

BAYERCROP.NS

(3.8)
Stock Price

6.596,40 INR

16.3% ROA

24.65% ROE

40.93x PER

Market Cap.

298.273.976.385,00 INR

1.65% DER

2.11% Yield

14.05% NPM

Bayer CropScience Limited Stock Analysis

Bayer CropScience Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bayer CropScience Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (28.05%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a low debt to equity ratio (3%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Net Profit Growth

This company's net profit has consistently grown over the last five years, indicating a strong financial performance and making it an attractive investment opportunity.

6 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

7 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

8 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (46.909), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

9 PBV

The stock's elevated P/BV ratio (8.9x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Bayer CropScience Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bayer CropScience Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Bayer CropScience Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bayer CropScience Limited Revenue
Year Revenue Growth
2003 8.488.005.000
2004 7.230.790.000 -17.39%
2005 7.278.451.000 0.65%
2006 7.278.451.000 0%
2007 11.633.517.000 37.44%
2008 13.940.049.000 16.55%
2009 16.247.619.000 14.2%
2010 20.386.841.000 20.3%
2011 22.044.000.000 7.52%
2012 26.260.000.000 16.05%
2013 31.462.000.000 16.53%
2014 36.153.000.000 12.98%
2015 36.441.000.000 0.79%
2016 27.178.000.000 -34.08%
2017 26.111.000.000 -4.09%
2018 26.021.000.000 -0.35%
2019 35.190.000.000 26.06%
2020 41.428.000.000 15.06%
2021 45.767.000.000 9.48%
2022 51.397.000.000 10.95%
2023 64.688.000.000 20.55%
2023 51.397.000.000 -25.86%
2024 65.248.000.000 21.23%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bayer CropScience Limited Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 158.000.000 100%
2013 202.000.000 21.78%
2014 222.000.000 9.01%
2015 181.000.000 -22.65%
2016 204.000.000 11.27%
2017 205.000.000 0.49%
2018 577.000.000 64.47%
2019 543.000.000 -6.26%
2020 558.000.000 2.69%
2021 749.000.000 25.5%
2022 831.000.000 9.87%
2023 0 0%
2023 685.000.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bayer CropScience Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 1.097.062.000
2004 1.377.946.000 20.38%
2005 1.002.032.000 -37.52%
2006 1.002.656.000 0.06%
2007 1.407.151.000 28.75%
2008 1.200.398.000 -17.22%
2009 1.249.161.000 3.9%
2010 0 0%
2011 430.000.000 100%
2012 550.000.000 21.82%
2013 596.000.000 7.72%
2014 598.000.000 0.33%
2015 663.000.000 9.8%
2016 703.000.000 5.69%
2017 717.000.000 1.95%
2018 872.000.000 17.78%
2019 1.105.000.000 21.09%
2020 1.119.000.000 1.25%
2021 1.030.000.000 -8.64%
2022 1.290.000.000 20.16%
2023 0 0%
2023 2.931.000.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bayer CropScience Limited EBITDA
Year EBITDA Growth
2003 1.276.131.000
2004 952.361.000 -34%
2005 1.266.973.000 24.83%
2006 1.266.973.000 0%
2007 1.142.804.000 -10.87%
2008 1.952.271.000 41.46%
2009 2.455.425.000 20.49%
2010 2.442.211.000 -0.54%
2011 3.046.000.000 19.82%
2012 4.380.000.000 30.46%
2013 5.089.000.000 13.93%
2014 6.062.000.000 16.05%
2015 4.948.000.000 -22.51%
2016 4.840.000.000 -2.23%
2017 4.480.000.000 -8.04%
2018 4.229.000.000 -5.94%
2019 7.850.000.000 46.13%
2020 8.592.000.000 8.64%
2021 8.639.000.000 0.54%
2022 9.881.000.000 12.57%
2023 12.840.000.000 23.05%
2023 9.695.000.000 -32.44%
2024 12.560.000.000 22.81%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bayer CropScience Limited Gross Profit
Year Gross Profit Growth
2003 4.163.148.000
2004 3.442.436.000 -20.94%
2005 2.751.218.000 -25.12%
2006 2.751.218.000 0%
2007 3.971.050.000 30.72%
2008 4.570.679.000 13.12%
2009 5.764.665.000 20.71%
2010 6.645.358.000 13.25%
2011 7.472.000.000 11.06%
2012 8.798.000.000 15.07%
2013 10.544.000.000 16.56%
2014 11.999.000.000 12.13%
2015 11.553.000.000 -3.86%
2016 10.711.000.000 -7.86%
2017 10.095.000.000 -6.1%
2018 11.148.000.000 9.45%
2019 15.970.000.000 30.19%
2020 16.843.000.000 5.18%
2021 18.993.000.000 11.32%
2022 23.237.000.000 18.26%
2023 24.324.000.000 4.47%
2023 23.237.000.000 -4.68%
2024 21.024.000.000 -10.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bayer CropScience Limited Net Profit
Year Net Profit Growth
2003 352.564.000
2004 263.604.000 -33.75%
2005 568.578.000 53.64%
2006 568.578.000 0%
2007 491.025.000 -15.79%
2008 944.595.000 48.02%
2009 1.272.535.000 25.77%
2010 1.315.441.000 3.26%
2011 1.390.000.000 5.36%
2012 11.617.000.000 88.03%
2013 2.895.000.000 -301.28%
2014 3.830.000.000 24.41%
2015 3.009.000.000 -27.28%
2016 2.910.000.000 -3.4%
2017 3.001.000.000 3.03%
2018 2.376.000.000 -26.3%
2019 4.745.000.000 49.93%
2020 4.931.000.000 3.77%
2021 6.453.000.000 23.59%
2022 7.582.000.000 14.89%
2023 8.916.000.000 14.96%
2023 7.405.000.000 -20.41%
2024 10.168.000.000 27.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bayer CropScience Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 12
2004 7 -83.33%
2005 14 57.14%
2006 14 0%
2007 12 -16.67%
2008 24 47.83%
2009 32 28.13%
2010 33 3.03%
2011 35 5.71%
2012 294 88.1%
2013 75 -292%
2014 105 27.88%
2015 87 -19.54%
2016 82 -6.1%
2017 86 4.65%
2018 55 -56.36%
2019 106 47.62%
2020 110 3.67%
2021 144 23.78%
2022 169 14.88%
2023 198 15.15%
2023 169 -17.86%
2024 226 25.66%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bayer CropScience Limited Free Cashflow
Year Free Cashflow Growth
2003 515.307.000
2004 1.354.727.000 61.96%
2005 169.531.000 -699.1%
2006 190.604.000 11.06%
2007 845.611.000 77.46%
2008 -141.308.000 698.42%
2009 7.527.000 1977.35%
2010 502.744.000 98.5%
2011 484.000.000 -3.87%
2012 -359.000.000 234.82%
2013 1.196.000.000 130.02%
2014 1.488.000.000 19.62%
2015 1.660.000.000 10.36%
2016 1.022.000.000 -62.43%
2017 777.000.000 -31.53%
2018 3.572.000.000 78.25%
2019 6.246.000.000 42.81%
2020 6.447.000.000 3.12%
2021 1.601.000.000 -302.69%
2022 5.320.000.000 69.91%
2023 0 0%
2023 9.285.000.000 100%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bayer CropScience Limited Operating Cashflow
Year Operating Cashflow Growth
2003 704.914.000
2004 1.565.391.000 54.97%
2005 365.711.000 -328.04%
2006 386.784.000 5.45%
2007 1.403.821.000 72.45%
2008 346.205.000 -305.49%
2009 823.589.000 57.96%
2010 1.242.594.000 33.72%
2011 1.067.000.000 -16.46%
2012 1.383.000.000 22.85%
2013 2.815.000.000 50.87%
2014 2.004.000.000 -40.47%
2015 1.964.000.000 -2.04%
2016 1.573.000.000 -24.86%
2017 1.214.000.000 -29.57%
2018 4.018.000.000 69.79%
2019 6.659.000.000 39.66%
2020 6.867.000.000 3.03%
2021 2.155.000.000 -218.65%
2022 6.093.000.000 64.63%
2023 0 0%
2023 9.742.000.000 100%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bayer CropScience Limited Capital Expenditure
Year Capital Expenditure Growth
2003 189.607.000
2004 210.664.000 10%
2005 196.180.000 -7.38%
2006 196.180.000 0%
2007 558.210.000 64.86%
2008 487.513.000 -14.5%
2009 816.062.000 40.26%
2010 739.850.000 -10.3%
2011 583.000.000 -26.9%
2012 1.742.000.000 66.53%
2013 1.619.000.000 -7.6%
2014 516.000.000 -213.76%
2015 304.000.000 -69.74%
2016 551.000.000 44.83%
2017 437.000.000 -26.09%
2018 446.000.000 2.02%
2019 413.000.000 -7.99%
2020 420.000.000 1.67%
2021 554.000.000 24.19%
2022 773.000.000 28.33%
2023 0 0%
2023 457.000.000 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bayer CropScience Limited Equity
Year Equity Growth
2003 2.419.733.000
2004 2.584.252.000 6.37%
2005 3.314.306.000 22.03%
2006 3.314.306.000 0%
2007 3.694.423.000 10.29%
2008 4.509.626.000 18.08%
2009 5.597.925.000 19.44%
2010 6.729.740.000 16.82%
2011 7.927.000.000 15.1%
2012 19.313.000.000 58.96%
2013 17.423.000.000 -10.85%
2014 20.329.000.000 14.29%
2015 17.559.000.000 -15.78%
2016 20.567.000.000 14.63%
2017 17.783.000.000 -15.66%
2018 18.834.000.000 5.58%
2019 25.725.000.000 26.79%
2020 25.503.000.000 -0.87%
2021 25.243.000.000 -1.03%
2022 27.121.000.000 6.92%
2023 28.494.000.000 4.82%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bayer CropScience Limited Assets
Year Assets Growth
2003 7.191.512.000
2004 5.745.152.000 -25.18%
2005 6.591.716.000 12.84%
2006 6.593.150.000 0.02%
2007 8.545.498.000 22.85%
2008 9.372.324.000 8.82%
2009 10.831.544.000 13.47%
2010 15.742.291.000 31.19%
2011 18.407.000.000 14.48%
2012 24.150.000.000 23.78%
2013 23.869.000.000 -1.18%
2014 27.736.000.000 13.94%
2015 24.383.000.000 -13.75%
2016 28.254.000.000 13.7%
2017 25.348.000.000 -11.46%
2018 29.015.000.000 12.64%
2019 38.357.000.000 24.36%
2020 42.393.000.000 9.52%
2021 43.529.000.000 2.61%
2022 46.786.000.000 6.96%
2023 45.971.000.000 -1.77%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bayer CropScience Limited Liabilities
Year Liabilities Growth
2003 4.771.779.000
2004 3.160.900.000 -50.96%
2005 3.277.410.000 3.55%
2006 3.278.844.000 0.04%
2007 4.851.075.000 32.41%
2008 4.862.698.000 0.24%
2009 5.233.619.000 7.09%
2010 9.012.551.000 41.93%
2011 10.480.000.000 14%
2012 4.837.000.000 -116.66%
2013 6.446.000.000 24.96%
2014 7.407.000.000 12.97%
2015 6.824.000.000 -8.54%
2016 7.687.000.000 11.23%
2017 7.565.000.000 -1.61%
2018 10.181.000.000 25.69%
2019 12.632.000.000 19.4%
2020 16.890.000.000 25.21%
2021 18.286.000.000 7.63%
2022 19.665.000.000 7.01%
2023 17.477.000.000 -12.52%

Bayer CropScience Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1153.88
Net Income per Share
162.14
Price to Earning Ratio
40.93x
Price To Sales Ratio
5.75x
POCF Ratio
556.48
PFCF Ratio
556.48
Price to Book Ratio
10.47
EV to Sales
5.54
EV Over EBITDA
32.27
EV to Operating CashFlow
535.64
EV to FreeCashFlow
535.64
Earnings Yield
0.02
FreeCashFlow Yield
0
Market Cap
298,27 Bil.
Enterprise Value
287,10 Bil.
Graham Number
1520.86
Graham NetNet
214.25

Income Statement Metrics

Net Income per Share
162.14
Income Quality
0.08
ROE
0.25
Return On Assets
0.16
Return On Capital Employed
0.3
Net Income per EBT
0.77
EBT Per Ebit
1.04
Ebit per Revenue
0.18
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
-0.02
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.4
Operating Profit Margin
0.18
Pretax Profit Margin
0.18
Net Profit Margin
0.14

Dividends

Dividend Yield
0.02
Dividend Yield %
2.11
Payout Ratio
0
Dividend Per Share
140

Operating Metrics

Operating Cashflow per Share
11.93
Free CashFlow per Share
11.93
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.24
Return on Tangible Assets
0.16
Days Sales Outstanding
67.58
Days Payables Outstanding
70.69
Days of Inventory on Hand
180.51
Receivables Turnover
5.4
Payables Turnover
5.16
Inventory Turnover
2.02
Capex per Share
0

Balance Sheet

Cash per Share
270,99
Book Value per Share
634,02
Tangible Book Value per Share
606.11
Shareholders Equity per Share
634.02
Interest Debt per Share
14.55
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
-1.26
Current Ratio
2.44
Tangible Asset Value
27,24 Bil.
Net Current Asset Value
21,58 Bil.
Invested Capital
28161000000
Working Capital
23,08 Bil.
Intangibles to Total Assets
0.03
Average Receivables
4,80 Bil.
Average Payables
3,03 Bil.
Average Inventory
7726000000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bayer CropScience Limited Dividends
Year Dividends Growth
2010 4
2011 4 0%
2012 4 0%
2013 5 20%
2014 10 44.44%
2015 17 47.06%
2016 17 0%
2017 17 0%
2018 18 5.56%
2019 18 0%
2020 115 84.35%
2021 150 23.33%
2022 125 -20%
2023 135 7.41%
2024 35 -285.71%

Bayer CropScience Limited Profile

About Bayer CropScience Limited

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and diagnostic imaging equipment and other contrast agents, including computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRiseTM and digital prediction systems that integrate data from farm equipment, satellites, field sensors, irrigation systems, drones, and other input sources and then analyze that data to allow farmers to make decisions through data science and predictive analytics. The company also exports its products. Bayer CropScience Limited was incorporated in 1958 and is based in Thane, India.

CEO
Mr. Simon Thorsten Wiebusch
Employee
1.317
Address
Bayer House
Thane, 400 607

Bayer CropScience Limited Executives & BODs

Bayer CropScience Limited Executives & BODs
# Name Age
1 Mr. Dinesh S. Bapat
Country Group Mngr of Environmental Science for India, Sri Lanka & for Nepal
70
2 Mr. Anil Jain
Vice President of Marketing & Co-operations
70
3 Ms. Shweta Rai
Country Division Head of the Pharmaceutical Division
70
4 Ms. Bharati Shetty
Company Secretary & Compliance Officer
70
5 Mr. Simon Thorsten Wiebusch
Vice Chairman, MD & Chief Executive Officer
70
6 Mr. Simon Johannes Britsch
Chief Financial Officer & Whole Time Director
70

Bayer CropScience Limited Competitors

Coromandel International Limited Logo
Coromandel International Limited

COROMANDEL.NS

(3.5)
Sanofi India Limited Logo
Sanofi India Limited

SANOFI.NS

(2.2)
PI Industries Limited Logo
PI Industries Limited

PIIND.NS

(2.8)
Dhanuka Agritech Limited Logo
Dhanuka Agritech Limited

DHANUKA.NS

(2.8)